Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Cytokinetics (Nasdaq: CYTK) announced that Robert I. Blum, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 9:45 AM PT in San Francisco.
Investors can watch a live webcast via the company's Investors & Media website, and a replay will be archived on the website for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – CYTK
In the Jan 6 session, CYTK gained 5.45%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 19 | FDA approval | Positive | +4.6% | FDA approval of MYQORZO for symptomatic oHCM, enabling U.S. launch. |
| Dec 17 | China approval | Positive | -3.5% | NMPA approval of MYQORZO in China with milestone payments and royalties. |
| Dec 16 | Inducement grants | Neutral | -0.2% | Stock options and RSUs granted to new hires under Nasdaq Rule 5635(c)(4). |
| Dec 12 | EU CHMP opinion | Positive | +4.3% | Positive CHMP opinion recommending EU marketing authorization for MYQORZO. |
| Nov 18 | Inducement grants | Neutral | -1.2% | Inducement RSUs and options granted to new executive and employees. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Regulatory milestones around MYQORZO have often coincided with positive price reactions, while routine equity and HR-related updates have tended to see flat-to-negative moves.
Over recent months, Cytokinetics has reported several major regulatory milestones for MYQORZO (aficamten), including a positive CHMP opinion on Dec 12, 2025, NMPA approval in China on Dec 17, 2025, and subsequent FDA approval on Dec 19, 2025. These events produced mixed but generally constructive price reactions, with EU and U.S. approvals drawing gains and the China approval seeing weakness. Alongside these catalysts, the company has announced multiple inducement equity grants, which have been associated with modest share-price pressure. Today’s conference appearance fits more with routine corporate communications than a new value-defining milestone.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 AM Pacific Time in San Francisco, CA.
Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO™ (aficamten) is a cardiac myosin inhibitor approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms by the U.S. Food and Drug Administration and the China National Medical Products Administration. The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten) with a decision expected from the European Commission in first quarter in 2026. Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
